ribosomal protein S4X pseudogene 9Genealiases: RPS4P9 · RPS4X_4_749
Q-omics provides the consensus-scored RPS4XP9 profile across patient tissues and cancer cell-line models. RPS4XP9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS4XP9 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RPS4XP9 RNA expression shows 8,510 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUSC, and GBM as cancer lineages where RPS4XP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP9 survival associations across molecular data types. RPS4XP9 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP9 RNA expression–survival associations across cancer types. High RPS4XP9 expression shows unfavorable associations in LUAD and COAD, but favorable associations in KIRC, KIRP, THCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS4XP9 RNA expression.
This table summarizes RPS4XP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP9 shows lower tumor expression in KIRC and higher tumor expression in LUSC, COAD, THCA, KIRC and LUAD. The LUSC box plot shows higher RPS4XP9 RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with RPS4XP9 in patient tissues and cancer cell lines. In patient samples, RPS4XP9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
